Geopolitics, US BIOSECURE: Pharma Looks To Redistribute CDMO Footprint

Biopharma firms are rethinking their contract development and manufacturing organization (CDMO) network against the backdrop of geopolitical tensions and the advancement of the US BIOSECURE legislation, but how dramatic, if at all, is the ex-China shift likely to be over the short and longer term?

Two distinct McKinsey surveys may perhaps indicate where things are headed, with a large percentage of respondents not keen to consider China as a primary sourcing destination for new products/projects,...